Table I.
HEIH expression | ||||
---|---|---|---|---|
Factors | Number of patients | Low (n=77) | High (n=83) | P-valuea |
Age, years | 0.188 | |||
<60 | 80 | 42 | 38 | |
≥60 | 80 | 35 | 45 | |
Family history | 0.472 | |||
Absent | 147 | 72 | 75 | |
Present | 13 | 5 | 8 | |
Tumor grade | 0.776 | |||
I–II | 125 | 62 | 63 | |
III | 35 | 15 | 20 | |
TNM stage | 0.006 | |||
I | 39 | 28 | 11 | |
II | 55 | 32 | 23 | |
III | 45 | 13 | 32 | |
IV | 21 | 4 | 17 | |
Lymph node metastasis | 0.017 | |||
Negative | 78 | 27 | 51 | |
Positive | 82 | 50 | 32 | |
ER status | 0.696 | |||
Negative | 87 | 43 | 44 | |
Positive | 73 | 34 | 39 | |
PR status | 0.574 | |||
Negative | 20 | 8 | 12 | |
Positive | 140 | 69 | 71 | |
HER2 status | 0.726 | |||
Negative | 47 | 22 | 25 | |
Positive | 113 | 55 | 58 |
Pearson's χ2 test. TNM, tumor-node-metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; lncRNA, long non-coding RNA; HEIH, high expression in hepatocellular carcinoma